Use of AB1 to Upregulate Fetal Hemoglobin in Patients With Sickle Cell Disease
In this podcast, Nirmish Shah, MD, discusses an overview, the results, and the preclinical and clinical impact of the study titled Preclinical and Clinical Use of AB1, a DNMT1 Protein Depleter, to Upregulate Fetal Hemoglobin in Townes Sickle Cell Disease (SCD) Mice and Patients with SCD. Dr Shah also presented on this topic at the American Society of Hematology\u2019s 2023 annual meeting\xa0in San Diego, CA.